Agreements Related to Acquired Intellectual Property Rights (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Lucid Diagnostics Inc [Member]
Shares of common stock percentage	81.85%	81.875%
CWRU License Agreement [Member] | Research and Development Expenses [Member]
Milestone payment		$ 75
Reimbursement of patent fees	$ 250	$ 200
CWRU License Agreement [Member] | General and Administrative Expense [Member]
Milestone payment	$ 100
CWRU License Agreement [Member] | Lucid Diagnostics Inc [Member]
Agreement description	The CWRU License Agreement terminates upon the expiration of certain related patents, or on May 12, 2038 in countries where no such patents exist, or upon expiration of any exclusive marketing rights granted by the FDA or other U.S. government agency, whichever comes later.
Description of equity interest percentage	The right, in its sole discretion, to require PAVmed Inc. to transfer to CWRU 80% of the shares of common stock of Lucid Diagnostics Inc.
Shares of common stock percentage	80.00%